相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Leucine Signals to mTORC1 via Its Metabolite Acetyl-Coenzyme A
Sung Min Son et al.
CELL METABOLISM (2019)
Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group
Martin Fenner et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Increased Serine and One-Carbon Pathway Metabolism by PKCλ/l Deficiency Promotes Neuroendocrine Prostate Cancer
Miguel Reina-Campos et al.
CANCER CELL (2019)
Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations
Adeola O. Adebayo Michael et al.
CELL METABOLISM (2019)
GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors
Johanna Chiche et al.
CELL METABOLISM (2019)
CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability
Seung H. Choi et al.
GENES & DEVELOPMENT (2019)
CD36 mediates palmitate acid-induced metastasis of gastric cancer via AKT/GSK-3/-catenin pathway
Jiaomeng Pan et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Identification and characterization of two novel oncogenic mTOR mutations
Avaniyapuram Kannan Murugan et al.
ONCOGENE (2019)
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma
Shuo Qie et al.
NATURE COMMUNICATIONS (2019)
The ability to utilise ammonia as nitrogen source is cell type specific and intricately linked to GDH, AMPK and mTORC1
Shervi Lie et al.
SCIENTIFIC REPORTS (2019)
IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype
Darya Alizadeh et al.
CANCER IMMUNOLOGY RESEARCH (2019)
VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer
Thomas Decker et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
The lysosomal GPCR-like protein GPR137B regulates Rag and mTORC1 localization and activity
Lin Gan et al.
NATURE CELL BIOLOGY (2019)
Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease
Varsha Prakash et al.
NATURE COMMUNICATIONS (2019)
GPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor
Jenna L. Jewell et al.
ELIFE (2019)
mTOR Inhibitors Can Enhance the Anti-Tumor Effects of DNA Vaccines through Modulating Dendritic Cell Function in the Tumor Microenvironment
Yu-Li Chen et al.
CANCERS (2019)
Targeting metabolism to regulate immune responses in autoimmunity and cancer
Chirag H. Patel et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
AMPK directly activates mTORC2 to promote cell survival during acute energetic stress
Dubek Kazyken et al.
SCIENCE SIGNALING (2019)
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival
Georgios Batsios et al.
SCIENTIFIC REPORTS (2019)
Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
Mi Na Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Laia Martinez-Carreres et al.
CANCER RESEARCH (2019)
A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor
Chiara Borsari et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Non-canonical mTORC2 Signaling Regulates Brown Adipocyte Lipid Catabolism through SIRT6-FoxO1
Su Myung Jung et al.
MOLECULAR CELL (2019)
mTOR: Role in cancer, metastasis and drug resistance
Avaniyapuram Kannan Murugan
SEMINARS IN CANCER BIOLOGY (2019)
Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer
Diane M. Demas et al.
FRONTIERS IN ONCOLOGY (2019)
Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma
Joseph J. Caumanns et al.
CANCER LETTERS (2019)
The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma
Brent Holmes et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
Sarah A. Best et al.
NATURE COMMUNICATIONS (2019)
The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
Charlotte M. Huijts et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma
Naomi B. Haas et al.
CLINICAL CANCER RESEARCH (2019)
The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity
David Digomann et al.
CLINICAL CANCER RESEARCH (2019)
mTOR as a central hub of nutrient signalling and cell growth
Joungmok Kim et al.
NATURE CELL BIOLOGY (2019)
Targeting the mTOR Signaling Pathway Utilizing Nanoparticles: A Critical Overview
Mariia Lunova et al.
CANCERS (2019)
CHCHD4 regulates tumour proliferation and EMT-related phenotypes, through respiratory chain-mediated metabolism
Luke W. Thomas et al.
CANCER & METABOLISM (2019)
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Yan Xing et al.
BREAST CANCER RESEARCH (2019)
Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression
Fang Ni et al.
NATURE METABOLISM (2019)
A phase Ib study of everolimus combined with metformin for patients with advanced cancer
Remco J. Molenaar et al.
INVESTIGATIONAL NEW DRUGS (2018)
Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naive Advanced Pancreatic Neuroendocrine Tumors
Ramon Salazar et al.
ONCOLOGIST (2018)
Who does TORC2 talk to?
Jianling Xie et al.
BIOCHEMICAL JOURNAL (2018)
α1A-Adrenoceptors activate mTOR signalling and glucose uptake in cardiomyocytes
Masaaki Sato et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Phase 1/2 Trial of Temsirolimus and Sorafenib in the Treatment of Patients With Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
David Schiff et al.
CANCER (2018)
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma
Milica Momcilovic et al.
CANCER CELL (2018)
Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase
Dana M. Gwinn et al.
CANCER CELL (2018)
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Jordi Rodon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors
Amikar Sehdev et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival
Thomas A. Werfel et al.
CANCER RESEARCH (2018)
Metabolic Determinants of Sensitivity to Phosphatidylinositol 3-Kinase Pathway Inhibitor in Small-Cell Lung Carcinoma
Hideki Makinoshima et al.
CANCER RESEARCH (2018)
Mammalian target of rapamycin complex 2 (mTORC2) controls glycolytic gene expression by regulating Histone H3 Lysine 56 acetylation
Raghavendra Vadla et al.
CELL CYCLE (2018)
Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma
Joseph J. Caumanns et al.
CLINICAL CANCER RESEARCH (2018)
Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma
Xin Gao et al.
CLINICAL GENITOURINARY CANCER (2018)
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
Laura Graham et al.
INVESTIGATIONAL NEW DRUGS (2018)
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102
Noah Kornblum et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
G6PD as a predictive marker for glioma risk, prognosis and chemosensitivity
Chin-An Yang et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
mTORC1 Promotes Metabolic Reprogramming by the Suppression of GSK3-Dependent Foxk1 Phosphorylation
Long He et al.
MOLECULAR CELL (2018)
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia
Andrew E. Place et al.
PEDIATRIC BLOOD & CANCER (2018)
RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition
Philip Earwaker et al.
PLOS ONE (2018)
TORC1 inhibition enhances immune function and reduces infections in the elderly
Joan B. Mannick et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
A small molecule inhibitor of Rheb selectively targets mTORC1 signaling
Sarah J. Mahoney et al.
NATURE COMMUNICATIONS (2018)
Loss of a Negative Regulator of mTORC1 Induces Aerobic Glycolysis and Altered Fiber Composition in Skeletal Muscle
Paul A. Dutchak et al.
CELL REPORTS (2018)
Large Intergenic Non-coding RNA-RoR Inhibits Aerobic Glycolysis of Glioblastoma Cells via Akt Pathway
Yong Li et al.
JOURNAL OF CANCER (2018)
Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer
In Hae Park et al.
JOURNAL OF CANCER (2018)
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial
Jennifer R. Brown et al.
LANCET HAEMATOLOGY (2018)
Modulation of G6PD affects bladder cancer via ROS accumulation and the AKT pathway in vitro
Xiaoyi Chen et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
mTORC2 modulates the amplitude and duration of GFAT1 Ser-243 phosphorylation to maintain flux through the hexosamine pathway during starvation
Joseph G. Moloughney et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
Benjamin D. Hopkins et al.
NATURE (2018)
Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer
Dennis Ruder et al.
Oncotarget (2018)
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
Alison M. Schram et al.
BRITISH JOURNAL OF CANCER (2018)
Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study
Vasilios Karavasilis et al.
TARGETED ONCOLOGY (2018)
Unraveling the Complex Interplay Between T Cell Metabolism and Function
Ramon I. Klein Geltink et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 36 (2018)
mTOR signalling and cellular metabolism are mutual determinants in cancer
Dirk Mossmann et al.
NATURE REVIEWS CANCER (2018)
A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas
Matteo M. Trucco et al.
CLINICAL SARCOMA RESEARCH (2018)
Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
Remy B. Verheijen et al.
CLINICAL PHARMACOKINETICS (2018)
Sirolimus in Infants with Multiple Cardiac Rhabdomyomas Associated with Tuberous Sclerosis Complex
Maurizio Lucchesi et al.
CASE REPORTS IN ONCOLOGY (2018)
Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition
S. T. Kim et al.
ANNALS OF ONCOLOGY (2017)
A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors
Christos E. Kyriakopoulos et al.
INVESTIGATIONAL NEW DRUGS (2017)
Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial
Tatiana C. Schneider et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Exogenous FABP4 increases breast cancer cell proliferation and activates the expression of fatty acid transport proteins
Sandra Guaita-Esteruelas et al.
MOLECULAR CARCINOGENESIS (2017)
Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease
Helma Freitag et al.
NEUROENDOCRINOLOGY (2017)
Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth
Y. Wang et al.
ONCOGENE (2017)
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors
Oren J. Becher et al.
PEDIATRIC BLOOD & CANCER (2017)
The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study
Peter Tan et al.
ONCOTARGET (2017)
RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR
Nneha Sakre et al.
ONCOTARGET (2017)
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
Christophe Massard et al.
EUROPEAN JOURNAL OF CANCER (2017)
Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours
A. Hollebecque et al.
EUROPEAN JOURNAL OF CANCER (2017)
Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas
Chengfeng Bi et al.
HAEMATOLOGICA (2017)
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors
Monica Mita et al.
INVESTIGATIONAL NEW DRUGS (2017)
Localization of mTORC2 activity inside cells
Michael Ebner et al.
JOURNAL OF CELL BIOLOGY (2017)
Low-dose controlled release of mTOR inhibitors maintains T cell plasticity and promotes central memory T cells
Joshua M. Gammon et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Regulation of glucose uptake in lymphoma cell lines by cMYC-and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability
Martina Broecker-Preuss et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT
Yuchao Gu et al.
MOLECULAR CELL (2017)
Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40
Haijuan Yang et al.
NATURE (2017)
Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma
Angelica Benavides-Serrato et al.
PLOS ONE (2017)
SAMTOR is an S-adenosylmethionine sensor for the mTORC1 pathway
Xin Gu et al.
SCIENCE (2017)
Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma
Elisa Oricchio et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
Trisha M. Wise-Draper et al.
TARGETED ONCOLOGY (2017)
Overexpression of Rictor protein in colorectal cancer is correlated with tumor progression and prognosis
Lifeng Wang et al.
ONCOLOGY LETTERS (2017)
Glucose-6-phosphate dehydrogenase and transketolase modulate breast cancer cell metabolic reprogramming and correlate with poor patient outcome
Adrian Benito et al.
ONCOTARGET (2017)
Effects of targeting SLC1A5 on inhibiting gastric cancer growth and tumor development in vitro and in vivo
Jian Lu et al.
ONCOTARGET (2017)
PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242
Chunmei Yang et al.
ONCOTARGET (2017)
A Positive Feedback Loop between Sestrin2 and mTORC2 Is Required for the Survival of Glutamine-Depleted Lung Cancer Cells
Jun-Kyu Byun et al.
CELL REPORTS (2017)
Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas
Chengfeng Bi et al.
HAEMATOLOGICA (2017)
Development of a new analog of SGK1 inhibitor and its evaluation as a therapeutic molecule of colorectal cancer
Xuchun Liang et al.
JOURNAL OF CANCER (2017)
mTORC2 Promotes Tumorigenesis via Lipid Synthesis
Yakir Guri et al.
CANCER CELL (2017)
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)
J. Martin-Broto et al.
ANNALS OF ONCOLOGY (2017)
Therapeutic inhibition of SGK1 suppresses colorectal cancer
Xuchun Liang et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2017)
Phase I Trial of Everolimus and Capecitabine in Metastatic HER2- Breast Cancer
Gregory A. Vidal et al.
CLINICAL BREAST CANCER (2017)
mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability
Alexander J. Valvezan et al.
CANCER CELL (2017)
mTORC1 Activator SLC38A9 Is Required to Efflux Essential Amino Acids from Lysosomes and Use Protein as a Nutrient
Gregory A. Wyant et al.
CELL (2017)
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer
Hope S. Rugo et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
AnEssential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis
Dina S. Stepanova et al.
CANCER RESEARCH (2017)
Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial
P. Christopoulos et al.
ANNALS OF ONCOLOGY (2017)
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
Howard A. Burris et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
The Dawn of the Age of Amino Acid Sensors for the mTORC1 Pathway
Rachel L. Wolfson et al.
CELL METABOLISM (2017)
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanovic et al.
CLINICAL CANCER RESEARCH (2017)
Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers
Hye Sook Chon et al.
BMC CANCER (2017)
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
Jose Baselga et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
Yiqun Zhang et al.
CANCER CELL (2017)
A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114)
Susan R. Rheingold et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
mTOR Signaling in Growth, Metabolism, and Disease (vol 168, pg 960, 2017)
Robert A. Saxton et al.
CELL (2017)
A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma
E. Jonasch et al.
ANNALS OF ONCOLOGY (2017)
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Qiwen Fan et al.
CANCER CELL (2017)
Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors
Yan Kong et al.
CLINICAL CANCER RESEARCH (2016)
PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancer
S-J Fan et al.
ONCOGENE (2016)
ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer
M. van Geldermalsen et al.
ONCOGENE (2016)
Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Jennifer R. Devlin et al.
CANCER DISCOVERY (2016)
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstrom's macroglobulinemia
Irene M. Ghobrial et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas
S. J. Kim et al.
ANNALS OF ONCOLOGY (2016)
Glutamine transporters in mammalian cells and their functions in physiology and cancer
Yangzom D. Bhutia et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
Emmanuel Seront et al.
BJU INTERNATIONAL (2016)
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies
Joaquin Mateo et al.
BRITISH JOURNAL OF CANCER (2016)
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)
Vicky Makker et al.
CANCER (2016)
mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer Cells
Raju V. Pusapati et al.
CANCER CELL (2016)
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma
Wei Wei et al.
CANCER CELL (2016)
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers
Muhammad R. Khawaja et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers
Meghan Morrison Joly et al.
CANCER RESEARCH (2016)
Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma
Yukiyoshi Hirayama et al.
CANCER SCIENCE (2016)
4E-BP1, a multifactor regulated multifunctional protein
Xiaoyu Qin et al.
CELL CYCLE (2016)
Amino Acid Sensing bymTORC1: Intracellular Transporters Mark the Spot
Deborah C. I. Goberdhan et al.
CELL METABOLISM (2016)
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
Saoirse O. Dolly et al.
CLINICAL CANCER RESEARCH (2016)
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma
Kathleen M. Mahoney et al.
CLINICAL GENITOURINARY CANCER (2016)
mTORC2 sustains thermogenesis via Akt-induced glucose uptake and glycolysis in brown adipose tissue
Verena Albert et al.
EMBO MOLECULAR MEDICINE (2016)
A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
Thomas Powles et al.
EUROPEAN UROLOGY (2016)
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation
Silvia F. Hernandez et al.
GYNECOLOGIC ONCOLOGY (2016)
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer
Josep Maria del Campo et al.
GYNECOLOGIC ONCOLOGY (2016)
Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)
Guenter Emons et al.
GYNECOLOGIC ONCOLOGY (2016)
Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma
Jessica L. Geiger et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
J. E. Grilley-Olson et al.
INVESTIGATIONAL NEW DRUGS (2016)
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin
Jianing Xu et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
Thomas Powles et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
mTOR inhibition potentiates cytotoxicity of Vγ4 γδ T cells via up-regulating NKG2D and TNF-α
Guangchao Cao et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma
Salah-Eddine Lamhamedi-Cherradi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al.
LANCET (2016)
mTORC2 Responds to Glutamine Catabolite Levels to Modulate the Hexosamine Biosynthesis Enzyme GFAT1
Joseph G. Moloughney et al.
MOLECULAR CELL (2016)
LKB1 loss links serine metabolism to DNA methylation and tumorigenesis
Filippos Kottakis et al.
NATURE (2016)
Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
Vanessa S. Rodrik-Outmezguine et al.
NATURE (2016)
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
Maria I. Carlo et al.
ONCOLOGIST (2016)
Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma
Vincent Chung et al.
ONCOLOGY (2016)
Role of SGK1 for fatty acid uptake, cell survival and radioresistance of NCI-H460 lung cancer cells exposed to acute or chronic cycling severe hypoxia
Johann Matschke et al.
RADIATION ONCOLOGY (2016)
mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle
Issam Ben-Sahra et al.
SCIENCE (2016)
Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
Xiaoyu Yang et al.
ONCOLOGY LETTERS (2016)
A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors
Andrew D. J. Pearson et al.
ONCOTARGET (2016)
Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen
James T. Lynch et al.
ONCOTARGET (2016)
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park et al.
ONCOTARGET (2016)
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
Xiaochun Liu et al.
ONCOTARGET (2016)
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma
Salah-Eddine Lamhamedi-Cherradi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase
Kosuke Toda et al.
NEOPLASIA (2016)
Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study
David N. Franz et al.
PLOS ONE (2016)
Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice
Junjie Hu et al.
SCIENTIFIC REPORTS (2016)
Toward rapamycin analog (rapalog)-based precision cancer therapy
Ling-hua Meng et al.
ACTA PHARMACOLOGICA SINICA (2015)
A liaison between mTOR signaling, ribosome biogenesis and cancer
Antonio Gentilella et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2015)
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor
Kimberly Blackwell et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
Z. Eroglu et al.
BRITISH JOURNAL OF CANCER (2015)
Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
Yasuhiro Oki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells
Theodosia Teo et al.
CANCER LETTERS (2015)
Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer
Hiroyuki Yamaguchi et al.
CANCER SCIENCE (2015)
Oral Ridaforolimus Plus Trastuzumab for Patients With HER2+ Trastuzumab-Refractory Metastatic Breast Cancer
Milton Seiler et al.
CLINICAL BREAST CANCER (2015)
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
Bristi Basu et al.
CLINICAL CANCER RESEARCH (2015)
A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies
Shilpa Gupta et al.
CLINICAL CANCER RESEARCH (2015)
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Naval Daver et al.
CLINICAL CANCER RESEARCH (2015)
Hexosamine pathway and (ER) protein quality control
Martin S. Denzel et al.
CURRENT OPINION IN CELL BIOLOGY (2015)
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
Johanna C. Bendell et al.
INVESTIGATIONAL NEW DRUGS (2015)
Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors
Matthew Zibelman et al.
INVESTIGATIONAL NEW DRUGS (2015)
mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation
Kristen N. Pollizzi et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma
Amit M. Oza et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development
Qian Wang et al.
JOURNAL OF PATHOLOGY (2015)
The S6K protein family in health and disease
Mariana R. Tavares et al.
LIFE SCIENCES (2015)
The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1α Phosphorylation
George J. Cerniglia et al.
MOLECULAR CANCER THERAPEUTICS (2015)
SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1
Manuele Rebsamen et al.
NATURE (2015)
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2015)
Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer
Urban Emmenegger et al.
ONCOLOGIST (2015)
Differential regulation of mTORC1 by leucine and glutamine
Jenna L. Jewell et al.
SCIENCE (2015)
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study
Ulka Vaishampayan et al.
UROLOGY (2015)
RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors
Haiying Cheng et al.
CANCER DISCOVERY (2015)
PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex
Pengda Liu et al.
CANCER DISCOVERY (2015)
Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy
Cristina Talarico et al.
Oncotarget (2015)
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
A. W. Tolcher et al.
ANNALS OF ONCOLOGY (2015)
Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Joseph G. Crompton et al.
CANCER RESEARCH (2015)
Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death
C-S Yang et al.
ONCOGENE (2015)
Phase II Study of Cixutumumab in Combination With Temsirolimus in Pediatric Patients and Young Adults With Recurrent or Refractory Sarcoma: A Report From the Children's Oncology Group
Lars M. Wagner et al.
PEDIATRIC BLOOD & CANCER (2015)
Combined MTOR and autophagy inhibition Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma
Reshma Rangwala et al.
AUTOPHAGY (2014)
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
Jasmeet Chadha Singh et al.
BREAST CANCER RESEARCH (2014)
Rab1A Is an mTORC1 Activator and a Colorectal Oncogene
Janice D. Thomas et al.
CANCER CELL (2014)
Protein and Nucleotide Biosynthesis Are Coupled by a Single Rate-Limiting Enzyme, PRPS2, to Drive Cancer
John T. Cunningham et al.
CELL (2014)
Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2014)
The mTORC1/S6K1 Pathway Regulates Glutamine Metabolism through the elF4B-Dependent Control of c-Myc Translation
Alfredo Csibi et al.
CURRENT BIOLOGY (2014)
The hexosamine biosynthesis pathway and O-GlcNAcylation maintain insulin-stimulated PI3K-PKB phosphorylation and tumour cell growth after short-term glucose deprivation
David R. Jones et al.
FEBS JOURNAL (2014)
Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer
Daliah Tsoref et al.
GYNECOLOGIC ONCOLOGY (2014)
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial
Andrew X. Zhu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Nitrogen Source Activates TOR (Target of Rapamycin) Complex 1 via Glutamine and Independently of Gtr/Rag Proteins
Daniele Stracka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2-Dependent and Other Solid Tumors
Leena Gandhi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide
Andrey A. Parkhitko et al.
MOLECULAR CANCER RESEARCH (2014)
Akt Phosphorylation and Regulation of Transketolase Is a Nodal Point for Amino Acid Control of Purine Synthesis
Arindam Saha et al.
MOLECULAR CELL (2014)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Fabrice Andre et al.
LANCET ONCOLOGY (2014)
Making new contacts: the mTOR network in metabolism and signalling crosstalk
Mitsugu Shimobayashi et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
Nikhil Wagle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
AZD8055 induces cell death associated with autophagy and activation of AMPK in hepatocellular carcinoma
Min Hu et al.
ONCOLOGY REPORTS (2014)
Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
Sharmila Mallya et al.
PLOS ONE (2014)
The mTOR Inhibitor Rapamycin Synergizes with a Fatty Acid Synthase Inhibitor to Induce Cytotoxicity in ER/HER2-Positive Breast Cancer Cells
Chen Yan et al.
PLOS ONE (2014)
SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas
Dimitrios Moraitis et al.
SURGERY (2014)
A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
Brian C. Grabiner et al.
CANCER DISCOVERY (2014)
Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia
Lise Willems et al.
BLOOD (2013)
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
N. Colombo et al.
BRITISH JOURNAL OF CANCER (2013)
The mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4
Alfred Csibi et al.
CELL (2013)
mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation
Masahiro Morita et al.
CELL METABOLISM (2013)
mTOR Complex 2 Controls Glycolytic Metabolism in Glioblastoma through FoxO Acetylation and Upregulation of c-Myc
Kenta Masui et al.
CELL METABOLISM (2013)
Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study
Hajime Asahina et al.
INVESTIGATIONAL NEW DRUGS (2013)
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Gregg L. Semenza
JOURNAL OF CLINICAL INVESTIGATION (2013)
Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
John J. Bissler et al.
LANCET (2013)
S6K1 determines the metabolic requirements for BCR-ABL survival
J. F. Barger et al.
ONCOGENE (2013)
Combined RNAi-Mediated Suppression of Rictor and EGFR Resulted in Complete Tumor Regression in an Orthotopic Glioblastoma Tumor Model
Maite Verreault et al.
PLOS ONE (2013)
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers
Michael Pourdehnada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1
Issam Ben-Sahra et al.
SCIENCE (2013)
Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis
Aaron M. Robitaille et al.
SCIENCE (2013)
Chemical Genetics of Rapamycin-Insensitive TORC2 in S. cerevisiae
Joseph I. Kliegman et al.
CELL REPORTS (2013)
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
B. Markman et al.
ANNALS OF ONCOLOGY (2012)
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
A. Naing et al.
BRITISH JOURNAL OF CANCER (2012)
The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas
Nokitaka Setsu et al.
CANCER (2012)
Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53
Megan J. Bywater et al.
CANCER CELL (2012)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c
Asami Hagiwara et al.
CELL METABOLISM (2012)
Phase I Trial of Everolimus Plus Sorafenib for Patients with Advanced Renal Cell Cancer
Robert J. Amato et al.
CLINICAL GENITOURINARY CANCER (2012)
V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis
Matthias Evert et al.
HEPATOLOGY (2012)
A phase I study of temsirolimus and metformin in advanced solid tumours
Mary J. MacKenzie et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
Maarten J. Deenen et al.
INVESTIGATIONAL NEW DRUGS (2012)
Glucose-6-phosphate dehydrogenase, NADPH, and cell survival
Robert C. Stanton
IUBMB LIFE (2012)
Role of p70S6K1-mediated Phosphorylation of eIF4B and PDCD4 Proteins in the Regulation of Protein Synthesis
Michael D. Dennis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
Sant P. Chawla et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Inhibition of Mechanistic Target of Rapamycin Promotes Dendritic Cell Activation and Enhances Therapeutic Autologous Vaccination in Mice
Eyal Amiel et al.
JOURNAL OF IMMUNOLOGY (2012)
Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials
Rodrigo Dienstmann et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Glutaminolysis Activates Rag-mTORC1 Signaling
Raul V. Duran et al.
MOLECULAR CELL (2012)
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
L. Willems et al.
LEUKEMIA (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Insulin stimulation of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase
Joshua L. Owen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma
Aadra P. Bhatt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer et al.
SCIENCE (2012)
Metabolic reprogramming in cancer: Unraveling the role of glutamine in tumorigenesis
Dania Daye et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2012)
Overexpression of G6PD is associated with poor clinical outcome in gastric cancer
Jixu Wang et al.
TUMOR BIOLOGY (2012)
PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
Filip Janku et al.
ONCOTARGET (2012)
Sirolimus Enhances the Magnitude and Quality of Viral-Specific CD8+T-Cell Responses to Vaccinia Virus Vaccination in Rhesus Macaques
A. P. Turner et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Amino Acid Signaling in TOR Activation
Joungmok Kim et al.
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 80 (2011)
mTORC2 targets AGC kinases through Sin1-dependent recruitment
Angus J. M. Cameron et al.
BIOCHEMICAL JOURNAL (2011)
A Phase 1 Study of Everolimus and Sorafenib for Metastatic Clear Cell Renal Cell Carcinoma
Andrea L. Harzstark et al.
CANCER (2011)
Lactate Dehydrogenase B Is Critical for Hyperactive mTOR-Mediated Tumorigenesis
Xiaojun Zha et al.
CANCER RESEARCH (2011)
Activation of mTORC2 by Association with the Ribosome
Vittoria Zinzalla et al.
CELL (2011)
mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
Timothy R. Peterson et al.
CELL (2011)
Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent Pathways
Jessica L. Yecies et al.
CELL METABOLISM (2011)
Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer
Ning Jin et al.
CLINICAL CANCER RESEARCH (2011)
Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress
Kathrin Zaugg et al.
GENES & DEVELOPMENT (2011)
Evidence for Direct Activation of mTORC2 Kinase Activity by Phosphatidylinositol 3,4,5-Trisphosphate
Xiaoqing Gan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets
Ryan D. Michalek et al.
JOURNAL OF IMMUNOLOGY (2011)
The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells
Heike Niessner et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia
C. Evangelisti et al.
LEUKEMIA (2011)
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency
Preeti Tandon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth
Qian Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells
Sven A. Lang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2010)
Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
Andrew C. Hsieh et al.
CANCER CELL (2010)
Targeting the PI3K signaling pathway in cancer
Kwok-Kin Wong et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2010)
mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide
Won Jun Oh et al.
EMBO JOURNAL (2010)
Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer
David Luyimbazi et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1
Katrin Duevel et al.
MOLECULAR CELL (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Myc proteins as therapeutic targets
W. C. Gustafson et al.
ONCOGENE (2010)
Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
T. Sato et al.
ONCOGENE (2010)
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
Virginia E. Kwitkowski et al.
ONCOLOGIST (2010)
Analysis of PTEN and HIF-1α and Correlation With Efficacy in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus Versus Interferon-α
Robert A. Figlin et al.
CANCER (2009)
Bidirectional Transport of Amino Acids Regulates mTOR and Autophagy
Paul Nicklin et al.
CELL (2009)
The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
Philipp Baumann et al.
EXPERIMENTAL CELL RESEARCH (2009)
The Phosphatidylinositol 3-Kinase/Akt Cassette Regulates Purine Nucleotide Synthesis
Wei Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
Carson C. Thoreen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Enhancing CD8 T-cell memory by modulating fatty acid metabolism
Erika L. Pearce et al.
NATURE (2009)
mTOR regulates memory CD8 T-cell differentiation
Koichi Araki et al.
NATURE (2009)
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism
Ping Gao et al.
NATURE (2009)
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
Saskia M. Brachmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Is Akt the Warburg kinase?-Akt-energy metabolism interactions and oncogenesis
R. Brooks Robey et al.
SEMINARS IN CANCER BIOLOGY (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
Immunoregulatory functions of mTOR inhibition
Angus W. Thomson et al.
NATURE REVIEWS IMMUNOLOGY (2009)
The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake
Xiuyun Jiang et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
TOR regulation of AGC kinases in yeast and mammals
Estela Jacinto et al.
BIOCHEMICAL JOURNAL (2008)
mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)
Juan M. Garcia-Martinez et al.
BIOCHEMICAL JOURNAL (2008)
MTORCI inhibitors: is temsirolimus in renal cancer telling us how they really work?
C. Le Tourneau et al.
BRITISH JOURNAL OF CANCER (2008)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs
Xiaoju Max et al.
CELL (2008)
SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
Thomas Porstmann et al.
CELL METABOLISM (2008)
Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling
Tsuneo Ikenoue et al.
EMBO JOURNAL (2008)
The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C
Valeria Facchinetti et al.
EMBO JOURNAL (2008)
Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2
Alfredo Toschi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells
Konstantinos G. Lasithiotakis et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
AMPK phosphorylation of raptor mediates a metabolic checkpoint
Dana M. Gwinn et al.
MOLECULAR CELL (2008)
Regulation of TORC1 by Rag GTPases in nutrient response
Eunjung Kim et al.
NATURE CELL BIOLOGY (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction
David R. Wise et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
Andrew Y. Choo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1
Yasemin Sancak et al.
SCIENCE (2008)
Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
Daniel Cho et al.
CLINICAL GENITOURINARY CANCER (2007)
HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation
John D. Gordan et al.
CANCER CELL (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients
Manuela Battaglia et al.
JOURNAL OF IMMUNOLOGY (2006)
Akt1 activation can augment hypoxia-inducible factor-1α expression by increasing protein translation through a mammalian target of rapamycin-independent pathway
Nabendu Pore et al.
MOLECULAR CANCER RESEARCH (2006)
The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice
Mei-Ling Chen et al.
GENES & DEVELOPMENT (2006)
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Reuben J. Shaw et al.
NATURE (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
GV Thomas et al.
NATURE MEDICINE (2006)
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
KR Molhoek et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime?
BC Fuchs et al.
SEMINARS IN CANCER BIOLOGY (2005)
Restraining PI3K: mTOR signalling goes back to the membrane
LS Harrington et al.
TRENDS IN BIOCHEMICAL SCIENCES (2005)
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex
J Brugarolas et al.
GENES & DEVELOPMENT (2004)
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
PK Majumder et al.
NATURE MEDICINE (2004)
Akt stimulates aerobic glycolysis in cancer cells
RL Elstrom et al.
CANCER RESEARCH (2004)
Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation
CJ Hu et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
TSC2 mediates cellular energy response to control cell growth and survival
K Inoki et al.
CELL (2003)
Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb
AR Tee et al.
CURRENT BIOLOGY (2003)
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
JB Brugarolas et al.
CANCER CELL (2003)
Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2
A Garami et al.
MOLECULAR CELL (2003)
Rapamycin induces Smad activity in prostate cancer cell lines
HG van der Poel et al.
UROLOGICAL RESEARCH (2003)
Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin
CC Hudson et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
The immuno suppress ant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation
T Peng et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-Kinase/Akt pathway
BD Manning et al.
MOLECULAR CELL (2002)
Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics
A Grolleau et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The CD28 signaling pathway regulates glucose metabolism
KA Frauwirth et al.
IMMUNITY (2002)
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis:: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression
E Laughner et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase
K Gottlob et al.
GENES & DEVELOPMENT (2001)
Regulation of cellular growth by the Drosophila target of rapamycin dTOR
HB Zhang et al.
GENES & DEVELOPMENT (2000)
分享论文
